1 September 2024
Shareholder Update: April 2012
In this issue:
› Starpharma commences pivotal phase 3 VivaGel® BV treatment trials
› Starpharma continues to build momentum as a leader in the sector
› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model
› Nanobiotechnology to reach $6 billion by 2017
Download: Shareholder Update: April 2012 ( pdf file, 1MB)